PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



WO 93/03724

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5: (11) International Publication Number: A61K 31/44, 31/64 // (A61K 31/64 A1 A61K 31:195) (A61K 31/44 (43) International Publication Date: 4 March 1993 (04.03.93) A61K 31:195)

(21) International Application Number: PCT/US92/06776

(22) International Filing Date: 19 August 1992 (19.08.92)

(30) Priority data: 26 August 1991 (26.08.91) 26 August 1991 (26.08.91) 750,559 US 751,239 US

(60) Parent Applications or Grants

(63) Related by Continuation US 750,559 (CIP) 26 August 1991 (26.08.91) 751,239 (CIP) Filed on US 26 August 1991 (26.08.91) Filed on

(71) Applicant (for all designated States except US): THE UP-JOHN COMPANY [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): MEGLASSON, Martin, Durham [US/US]; 5337 Whippoorwill, Kalamazoo, MI 49002 (US).

(74) Agent: GAMMILL, Martha, A.; Corporate Intellectual Property Law, The Upjohn Company, 301 Henrietta Street, Kalamazoo, MI 49001 (US).

(81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL COMPOSITION CONTAINING 3-GUANIDINOPROPIONIC ACID AND PIOGLITA-ZONE GLIBENCLAMIDE OR GLIMEPIRIDE

(57) Abstract

The present invention provides a new composition, food product and uses for a known compound. More particularly, the present invention provides a new pharmaceutical composition containing 3-guanidinopropionic acid and a method of using 3-guanidinopropionic acid to prevent or treat obesity in non-insulin dependent diabetic (NIDDM) patients that is caused by treatment with anti-diabetic drugs, such as an insulin sensitizing drug or an insulin secretion stimulating drug. Examples of insulin sensitizing drugs are pioglitazone and pioglitazone hydrochloride. Examples of insulin secretion stimulating drugs are glyburide and glimepiride. The present invention also provides a new food product containing 3-guanidinopropionic acid and a method of using 3-guanidinopropionic acid to increase endurance, stamina and exercise capacity.

Ÿ